Compare BOTJ & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BOTJ | ATYR |
|---|---|---|
| Founded | 1998 | 2005 |
| Country | United States | United States |
| Employees | N/A | 58 |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 95.9M | 82.6M |
| IPO Year | 2015 | N/A |
| Metric | BOTJ | ATYR |
|---|---|---|
| Price | $23.56 | $0.84 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $3.67 |
| AVG Volume (30 Days) | 7.0K | ★ 821.7K |
| Earning Date | 05-12-2026 | 05-01-2026 |
| Dividend Yield | ★ 1.92% | N/A |
| EPS Growth | ★ 13.71 | N/A |
| EPS | ★ 1.99 | N/A |
| Revenue | ★ $4,273,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.75 | ★ N/A |
| Revenue Growth | ★ 6.74 | N/A |
| 52 Week Low | $13.03 | $0.64 |
| 52 Week High | $23.71 | $7.29 |
| Indicator | BOTJ | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 66.64 | 53.23 |
| Support Level | $20.18 | $0.67 |
| Resistance Level | N/A | $0.86 |
| Average True Range (ATR) | 0.37 | 0.04 |
| MACD | -0.04 | 0.01 |
| Stochastic Oscillator | 78.77 | 73.05 |
Bank of the James Financial Group Inc is a bank holding company that provides retail and commercial banking, deposit services, lending services, mortgage brokerage services, and other banking services. The company provides a range of deposit services including checking accounts, savings accounts and other time deposits of various types, ranging from daily money market accounts to longer-term certificates of deposit. It offers various types of secured and unsecured consumer loans, including personal loans, lines of credit, overdraft lines of credit, automobile loans, installment loans, demand loans, and home equity loans. It operates three business segments community banking; mortgage banking, and investment advisory services.
aTyr Pharma Inc is a clinical-stage biotechnology company focused on developing therapies for fibrosis and inflammatory conditions. Its research leverages tRNA synthetase biology to identify potential therapeutic targets. The company's discovery platform uses a proprietary library of domains derived from tRNA synthetases to explore signaling pathways. Its flagship clinical candidate, efzofitimod, is a novel biologic immunomodulatory in development for the treatment of interstitial lung disease (ILD).